These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34274223)

  • 21. Re-irradiation with stereotactic body radiation therapy (SBRT).
    Høyer M
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S15. PubMed ID: 28917253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
    Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External radiotherapy for prostatic cancers.
    de Crevoisier R; Supiot S; Créhange G; Pommier P; Latorzeff I; Chapet O; Pasquier D; Blanchard P; Schick U; Marchesi V; Sargos P; Hennequin C
    Cancer Radiother; 2022; 26(1-2):329-343. PubMed ID: 34955419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extreme Hypofractionation with SBRT in Localized Prostate Cancer.
    Gómez-Aparicio MA; Valero J; Caballero B; García R; Hernando-Requejo O; Montero Á; Gómez-Iturriaga A; Zilli T; Ost P; López-Campos F; Couñago F
    Curr Oncol; 2021 Aug; 28(4):2933-2949. PubMed ID: 34436023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL).
    Murthy V; Mallick I; Gavarraju A; Sinha S; Krishnatry R; Telkhade T; Moses A; Kannan S; Prakash G; Pal M; Menon S; Popat P; Rangarajan V; Agarwal A; Kulkarni S; Bakshi G
    BMJ Open; 2020 Feb; 10(2):e034623. PubMed ID: 32114475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
    Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
    Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer.
    Mallick I; Arunsingh M; Chakraborty S; Arun B; Prasath S; Roy P; Dabkara D; Achari R; Chatterjee S; Gupta S
    Clin Oncol (R Coll Radiol); 2020 Feb; 32(2):e39-e45. PubMed ID: 31551125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
    Meier RM; Bloch DA; Cotrutz C; Beckman AC; Henning GT; Woodhouse SA; Williamson SK; Mohideen N; Dombrowski JJ; Hong RL; Brachman DG; Linson PW; Kaplan ID
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):296-303. PubMed ID: 30191864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Body Radiotherapy for Primary Prostate Cancer.
    Kothari G; Loblaw A; Tree AC; van As NJ; Moghanaki D; Lo SS; Ost P; Siva S
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818789633. PubMed ID: 30064301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer.
    Loi M; Di Cataldo V; Simontacchi G; Detti B; Bonomo P; Masi L; Desideri I; Greto D; Francolini G; Carfora V; Pezzulla D; Perna M; Carta GA; Livi L
    Clin Oncol (R Coll Radiol); 2018 Feb; 30(2):93-100. PubMed ID: 29208480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial.
    McBride SM; Wong DS; Dombrowski JJ; Harkins B; Tapella P; Hanscom HN; Collins SP; Kaplan ID
    Cancer; 2012 Aug; 118(15):3681-90. PubMed ID: 22170628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic body radiation therapy for prostate cancer-a review.
    Haque W; Butler EB; Teh BS
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hypofractionated radiotherapy in prostate cancer].
    Supiot S; Créhange G; Latorzeff I; Pommier P; Paumier A; Rio E; Delaroche G; Guérif S; Catton C; Martin J; Lisbona A
    Cancer Radiother; 2013 Oct; 17(5-6):349-54. PubMed ID: 23973460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reirradiation of Pediatric Tumors Using Hypofractionated Stereotactic Radiotherapy.
    Gultekin M; Cengiz M; Sezen D; Zorlu F; Yildiz F; Yazici G; Hurmuz P; Ozyigit G; Akyol F; Gurkaynak M
    Technol Cancer Res Treat; 2017 Apr; 16(2):195-202. PubMed ID: 27352857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypofractionated radiotherapy for non-metastatic bone and soft tissue sarcomas.
    Yuce Sari S; Cengiz M; Dauletkazin A; Yazici G; Gultekin M; Hurmuz P; Yildiz F; Zorlu F; Gurkaynak M; Akyol F; Ozyigit G
    Cancer Radiother; 2019 Dec; 23(8):853-859. PubMed ID: 31640927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prostate cancer: what treatment techniques for which tumors? Ethical and methodological issues].
    de Crevoisier R; Castelli J; Guérif S; Pommier P; Créhange G; Chauvet B; Lagrange JL
    Cancer Radiother; 2014 Oct; 18(5-6):369-78. PubMed ID: 25199865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.